Screener
Lexicon Pharmaceuticals LXRX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 692 | 28,866 | 21,794 | 30,128 |
| Operating expenses: | ||||
| Cost of sales | 39 | 33 | 147 | 63 |
| Research and development | 16,059 | 14,127 | 27,446 | 27,736 |
| Sales and marketing | 834 | 1,233 | 1,915 | 3,908 |
| General and administrative | 6,964 | 6,466 | 13,408 | 14,292 |
| Other segment expense (1) | 3,336 | 3,271 | 6,414 | 6,072 |
| Total operating expenses | 27,232 | 25,130 | 49,330 | 52,071 |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's business segments — R&D?
- Lexicon Pharmaceuticals (LXRX) reported business segments — R&D of $16.06M in Q2 2026.
- How has Lexicon Pharmaceuticals's business segments — R&D changed year-over-year?
- Lexicon Pharmaceuticals's business segments — R&D increased by 13.7% year-over-year, from $14.13M to $16.06M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — R&D?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — R&D has grown at a 4.2% compound annual growth rate (CAGR), from $48.27M to $54.59M.
- What does business segments — R&D mean?
- Expenditures dedicated to the discovery, clinical testing, and development of new products or the enhancement of existing technologies within the segment. For biopharmaceutical companies, this is a critical investment metric reflecting the pipeline's potential for future growth. High spending indicates a commitment to innovation, though it directly impacts short-term profitability.
Ask your AI about Lexicon Pharmaceuticals's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude